retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Transforming obesity: The advancement of

statements regarding future collaborations or expanded access to treatment options

Glutathione plays an important role in protecting the body against oxidative stress and supporting liver detoxification processes

Reliable guidelines based on high-quality data from studies assessing a cause-and-effect relationship between GLP-1 RA use and RGC, aspiration, and regurgitation events are therefore more important than ever

Your BMI and Comorbidities Still Meet Surgical Criteria Adults qualify for bariatric surgery with a BMI of 35 or higher with at least one obesity-related health condition (such as type 2 diabetes, hypertension, or sleep apnea), or for those with a BMI of 40 or higher regardless of comorbidities

10.1371/journal.pone.0126312 462 WangJ.LiuX.LiQ

Why Women in Menopause & Perimenopause Struggle With Weight Loss During perimenopause and menopause , estrogen and progesterone levels fluctuate, impacting metabolism, fat storage, and insulin response